Bernie Sanders says Ozempic can be produced for less than $100 a month
Sen. Sanders claims that the CEOs of major generic drugmakers said they produce and sell Ozempic for less $100 a month.
Cheap Ozempic is coming: Cost could soon be slashed for millions of Americans, drugmaker confirms — here’s how
Get the skinny on this. Novo Nordisk, the Danish pharmaceutical company that manufactures Ozempic, said that it is “very likely” the cost of the popular diabetes-turned-weight loss drug will be cut in the second round of Medicare drug price negotiations.
Novo Says Ozempic ‘Very Likely’ Target for Next US Price Cut
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program, a company executive said.
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first cycle of negotiations.
US Senator Sanders Says Generic Drugmakers Could Sell Ozempic for Less Than $100/month
U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they could sell copycat versions of Novo Nordisk's diabetes drug Ozempic for less than $100 a month.
Ozempic Could Soon Be Cheaper in US
Ozempic dose. The type 2 diabetes drug, which can also cause weight loss, may be about to get cheaper. Ozempic dose. The type 2 diabetes drug, which can also cause weight loss, ma
The winding, fitful path to weight loss drug Ozempic
Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic—so ...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Ozempic ‘very likely’ to see prices slashed in drug price negotiations
The ability to negotiate drug prices is part of a sweeping set of policies in President Joe Biden’s Inflation Reduction Act.
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
JD Supra2d
Ozempic Lawsuit Update: New Study Links Semaglutides to Increased Risk of Vision Loss
More plaintiffs are continuing to join the diabetes drug Ozempic lawsuits against Novo Nordisk; and, until a couple of weeks ...
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Maker of Ozempic, Wegovy sues Minnesota clinic over knockoff weight-loss medication
One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...